TOP

 

 Brain Tumors

 Clasification

 Diagnosis

 Treatment

 Prognosis

 Experimental Treatments

 Stem Cells

 Information for:

  Profesionals

      - Physcicians

     - Researchers

  Non Profesionals

    - Pacientes

    - Familiares

 Useful Information

 Associations

 Foundations

 Medical Journals

 Research Grants

 Useful Links

 

 

GLIOBLASTOMA MULTIFORME (GBM)

GBM is a glioma and the most common type of primary brain tumor. Gliomas are classified by the World Health Organization into 4 distinct grades based on histological features of cellularity, nuclear morphology, mitotic activity, necrosis, and vascular proliferation (Louis=et alK, 2007).

A higher histologic grade corresponds to a less differentiated phenotype and to increasing malignancy. The most common form, a grade IV glioma, is called glioblastoma multiforme (GBM).

Accounts for more than one half of all gliomas and 15% to 20% of intracranial tumors, GBM is the most common malignant primary brain tumor. It may occur at any age but most commonly affects adults, with a peak incidence between 45 and 70 years of age. GBMs usually occur within the subcortical white matter, where they may present de novo as a primary GBM or after dedifferentiation from lower-grade glioma (secondary). It is thought that 60% of these tumors are de novo in adults older than the age of 50 years. Secondary GBM typically develops in younger patients under the age of 45 years through malignant progression from a low-grade astrocytoma or AA.

To read more about GBM, clik on the specific links (In Green) on the left.

 

 

 

  

   

     
   

 

   

 

   

 

 

 

 

 

Selected References

 
 

- Adamson C, Kanu OO, Mehta AI, Di C, Lin N, Mattox AK, Bigner DD. Glioblastoma multiforme: a review of where we have been and where we are going. Expert Opin Investig Drugs. 2009 Aug;18(8):1061-83.

 

- Baeza N, Weller M, Yonekawa Y, Kleihues P, Ohgaki H. PTEN methylation and expression in glioblastomas. Acta Neuropathol. 2003 Nov;106(5):479-85.

 

- Barth RF. Rat brain tumor models in experimental neuro-oncology: the 9L, C6, T9, F98, RG2 (D74), RT-2 and CNS-1 gliomas. J Neurooncol. 1998 Jan;36(1):91-102.

 

- Barth RF, Yang W, Coderre JA. Rat brain tumor models to assess the efficacy of boron neutron capture therapy: a critical evaluation. J Neurooncol. 2003 Mar-Apr;62(1-2):61-74.

 

- Barth RF, Joensuu H. Boron neutron capture therapy for the treatment of glioblastomas and extracranial tumours: as effective, more effective or less effective than photon irradiation? Radiother Oncol. 2007 Feb;82(2):119-22. Epub 2007 Feb 8.

 

- Biernat W, Huang H, Yokoo H, Kleihues P, Ohgaki H. Predominant expression of mutant EGFR (EGFRvIII) is rare in primary glioblastomas. Brain Pathol. 2004 Apr;14(2):131-6.

 

- Farrell CJ, Plotkin SR. Genetic causes of brain tumors: neurofibromatosis, tuberous sclerosis, von Hippel-Lindau, and other syndromes. Neurol Clin. 2007 Nov;25(4):925-46, viii. Review.

 

- Glas M, Happold C, Rieger J, Wiewrodt D, Bähr O, Steinbach JP, Wick W, Kortmann RD, Reifenberger G, Weller M, Herrlinger U. Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide. J Clin Oncol. 2009 Mar 10;27(8):1257-61.

 

- Kanu OO, Mehta A, Di C, Lin N, Bortoff K, Bigner DD, Yan H, Adamson DC. Glioblastoma multiforme: a review of therapeutic targets. Expert Opin Ther Targets. 2009 Jun;13(6):701-18.

 

- Lawler S, Chiocca EA. Emerging functions of microRNAs in glioblastoma. J Neurooncol. 2009 May;92(3):297-306. Epub 2009 Apr 9. Review.

 

- Martinez R, Schackert G, Yaya-Tur R, Rojas-Marcos I, Herman JG, Esteller M. Frequent hypermethylation of the DNA repair gene MGMT in long-term survivors of glioblastoma multiforme. J Neurooncol. 2007 May;83(1):91-3.

 

- Martinez R, Setien F, Voelter C, Casado S, Quesada MP, Schackert G, Esteller M. CpG island promoter hypermethylation of the pro-apoptotic gene caspase-8 is a common hallmark of relapsed glioblastoma multiforme. Carcinogenesis. 2007 Jun;28(6):1264-8.

 

- Martinez R, Schackert G, Esteller M. Hypermethylation of the proapoptotic gene TMS1/ASC: prognostic importance in glioblastoma multiforme. J Neurooncol. 2007 Apr;82(2):133-9.

 

- Martinez R, Martin-Subero JI, Rohde V, Kirsch M, Alaminos M, Fernandez AF, Ropero S, Schackert G, Esteller M. A microarray-based DNA methylation study of glioblastoma multiforme. Epigenetics. 2009 May;4(4):255-64

 

- Mechtler L. Neuroimaging in neuro-oncology. . Neurol Clin. 2009 Feb;27(1):171-201, ix. Review.

 

- Nagarajan RP, Costello JF. Epigenetic mechanisms in glioblastoma multiforme. Semin Cancer Biol. 2009 Jun;19(3):188-97. Epub 2009 Feb 20. Review.

 

- Novakova J, Slaby O, Vyzula R, Michalek J. MicroRNA involvement in glioblastoma pathogenesis. Biochem Biophys Res Commun. 2009 Aug 14;386(1):1-5.

 

- Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre PL, Burkhard C, Schüler D, Probst-Hensch NM, Maiorka PC, Baeza N, Pisani P, Yonekawa Y, Yasargil MG, Lütolf UM, Kleihues P. Genetic pathways to glioblastoma: a population-based study. Cancer Res. 2004 Oct 1;64(19):6892-9.

 

- Ohgaki H. Epidemiology of brain tumors.  Methods Mol Biol. 2009;472:323-42. Review.

 

- Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol. 2007 May;170(5):1445-53. Review.

 

- Olson JJ, Fadul CE, Brat DJ, Mukundan S, Ryken TC.  Management of newly diagnosed glioblastoma: guidelines development, value and application. J Neurooncol. 2009 May;93(1):1-23.

 

- Sperduto CM, Chakravarti A, Aldape K, Burger P, Papermaster GB, Sperduto P. Twenty-Year Survival In Glioblastoma: A Case Report And Molecular Profile. Sperduto CM, Chakravarti A, Aldape K, Burger P, Papermaster GB, Sperduto P. Int J Radiat Oncol Biol Phys. 2009 Mar 25.

 

- Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005 Mar 10;352(10):987-96.

 

- Sulman EP, Guerrero M, Aldape K. Beyond grade: molecular pathology of malignant gliomas. Semin Radiat Oncol. 2009 Jul;19(3):142-9.

- Wen PY, Kesari S.Malignant gliomas in adults. N Engl J Med. 2008 Jul 31;359(5):492-507.

- Yamamoto T, Nakai K, Matsumura A. Boron neutron capture therapy for glioblastoma. Cancer Lett. 2008 Apr 18;262(2):143-52.

- Yang W, Barth RF, Wu G, Ciesielski MJ, Fenstermaker RA, Moffat BA, Ross BD, Wikstrand CJ. Development of a syngeneic rat brain tumor model expressing EGFRvIII and its use for molecular targeting studies with monoclonal antibody L8A4. Clin Cancer Res. 2005 Jan 1;11(1):341-50.

 

 

     
  Search more...